Consecutive patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism who had completed at least 6 months of anticoagulant therapy were randomly assigned in a 1:1 ratio ...

Among over 12,000 patients in 11 high-risk groups, there were no differences in the prevention of pulmonary embolism, proximal deep vein thrombosis (DVT), or bleeding complications between those ...

The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...

The primary efficacy endpoint of METHRO III was the rate of total VTE (DVT plus pulmonary embolism [PE]) or unexplained death. The secondary endpoint was major VTE events, defined as proximal DVT ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...